Skip to main content

Master of Public Health

A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.

AUTHORS

Uronis HE , Jia J , Bendell JC , Howard L , Ready NA , Lee PH , Starr MD , Dellinger A , Pang H , Nixon AB , Hurwitz HI , . Cancer chemotherapy and pharmacology. 2014 12 20; ().

ABSTRACT

Inhibition of tumor angiogenesis is an effective mechanism to limit tumor growth; dual inhibition may result in additional benefit. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor (VEGF), and intetumumab is a fully humanized monoclonal antibody that blocks αv integrins when complexed with β integrins. We evaluated the safety, tolerability, and efficacy of the combination of bevacizumab plus intetumumab in patients with refractory solid tumors. We also explored the effects of these agents on plasma-based biomarkers and wound angiogenesis.

Inhibition of tumor angiogenesis is an effective mechanism to limit tumor growth; dual inhibition may result in additional benefit. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor (VEGF), and intetumumab is a fully humanized monoclonal antibody that blocks αv integrins when complexed with β integrins. We evaluated the safety, tolerability, and efficacy of the combination of bevacizumab plus intetumumab in patients with refractory solid tumors. We also explored the effects of these agents on plasma-based biomarkers and wound angiogenesis.

Tags: